image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.6783
5.83 %
$ 11.2 M
Market Cap
-1.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SSKN stock under the worst case scenario is HIDDEN Compared to the current market price of 2.68 USD, STRATA Skin Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SSKN stock under the base case scenario is HIDDEN Compared to the current market price of 2.68 USD, STRATA Skin Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SSKN stock under the best case scenario is HIDDEN Compared to the current market price of 2.68 USD, STRATA Skin Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SSKN

image
$3.4$3.4$3.3$3.3$3.2$3.2$3.1$3.1$3.0$3.0$2.9$2.9$2.8$2.8$2.7$2.7$2.6$2.6$2.5$2.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
33.6 M REVENUE
0.61%
-9.26 M OPERATING INCOME
-7.57%
-10.1 M NET INCOME
6.87%
188 K OPERATING CASH FLOW
136.22%
-1.64 M INVESTING CASH FLOW
67.40%
1.92 M FINANCING CASH FLOW
-71.94%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-4.5 M NET INCOME
-111.92%
703 K OPERATING CASH FLOW
332.78%
-504 K INVESTING CASH FLOW
-712.90%
0 FINANCING CASH FLOW
0.00%
Balance Sheet STRATA Skin Sciences, Inc.
image
Current Assets 16.6 M
Cash & Short-Term Investments 7.26 M
Receivables 5.25 M
Other Current Assets 4.08 M
Non-Current Assets 19.6 M
Long-Term Investments 0
PP&E 11.3 M
Other Non-Current Assets 8.24 M
20.08 %14.53 %11.29 %31.32 %22.78 %Total Assets$36.2m
Current Liabilities 14.6 M
Accounts Payable 2.43 M
Short-Term Debt 656 K
Other Current Liabilities 11.5 M
Non-Current Liabilities 16.6 M
Long-Term Debt 919 K
Other Non-Current Liabilities 15.6 M
7.80 %36.99 %2.95 %50.16 %Total Liabilities$31.2m
EFFICIENCY
Earnings Waterfall STRATA Skin Sciences, Inc.
image
Revenue 33.6 M
Cost Of Revenue 14.5 M
Gross Profit 19.1 M
Operating Expenses 28.3 M
Operating Income -9.26 M
Other Expenses 831 K
Net Income -10.1 M
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)34m(14m)19m(28m)(9m)(831k)(10m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
56.85% GROSS MARGIN
56.85%
-27.58% OPERATING MARGIN
-27.58%
-30.05% NET MARGIN
-30.05%
-202.86% ROE
-202.86%
-27.90% ROA
-27.90%
-41.02% ROIC
-41.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis STRATA Skin Sciences, Inc.
image
4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -10.1 M
Depreciation & Amortization 5.31 M
Capital Expenditures -1.64 M
Stock-Based Compensation 427 K
Change in Working Capital 688 K
Others 6.15 M
Free Cash Flow -1.45 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets STRATA Skin Sciences, Inc.
image
SSKN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership STRATA Skin Sciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.51 M USD 3
9-12 MONTHS
7. News
STRATA Skin Sciences, Inc. (SSKN) Q4 2024 Earnings Call Transcript Start Time: 16:30 January 1, 0000 5:00 PM ET STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q4 2024 Earnings Conference Call March 27, 2025, 16:30 PM ET Company Participants Dolev Rafaeli - CEO John Gillings - VP of Finance Louie Toma - CORE IR Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc. Fourth Quarter and Year End 2024 Financial Results and Corporate Update Conference Call. seekingalpha.com - 1 month ago
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update. globenewswire.com - 1 month ago
STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. globenewswire.com - 1 month ago
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled “Excimer Laser Penetrates Deeper into Hair Follicles and Activates More Melanocyte Lineage Cells than Excimer Light,” authored by distinguished researchers from the Nippon Medical School and published in the peer reviewed Journal of Nippon Medical School, demonstrates that despite the two devices producing same 308-nm wavelength, the distinct technological characteristics between two devices can have significant impact on the clinical outcomes. Notably, the excimer laser exhibits laser properties (monochromatic coherent light) and unique device specifications (a high frequency of 400 Hz and a remarkably high irradiance that leads to cellular differences such as deeper penetration, greater activation of melanocyte lineage cells (melanocyte stem cells (McSCs) and melanoblasts) resulting in superior clinical outcomes in terms of greater pigmentation and fewer epidermal side effects relative to excimer light. This study provides further scientific evidence that the modality generating UVB light has significant impact on the clinical outcomes of a device. globenewswire.com - 1 month ago
Why Fast-paced Mover Strata Skin Sciences (SSKN) Is a Great Choice for Value Investors Strata Skin Sciences (SSKN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 3 months ago
STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City. globenewswire.com - 4 months ago
STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript seekingalpha.com - 5 months ago
STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2024 and provides a corporate update. globenewswire.com - 5 months ago
STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that the United States District Court for the Eastern District of Pennsylvania entered a court order in favor of the Company in its complaint against LaserOptek America Corp. (“LaserOptek”), Monarch Aesthetic Services, Inc. d/b/a Monarch Laser Services (“MLS”), and The Pinnacle Health Group (“Pinnacle”), collectively referred to as the “Defendants.” globenewswire.com - 5 months ago
STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close. globenewswire.com - 5 months ago
STRATA Skin Sciences' XTRAC® Excimer Laser was Focus of Two Lectures at Major Japanese Annual Dermatology Conference HORSHAM, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that JMEC Co., Ltd., its longstanding Japanese strategic partner and distributor, sponsored a seminar with two lectures on XTRAC® excimer devices on Saturday, October 12, 2024, at the 75th Annual Meeting of the Chubu Branch of the Japanese Dermatological Association held in Nagoya, Japan. Professor Kazutoshi Harada of Tokyo Medical University chaired the seminar. globenewswire.com - 6 months ago
STRATA Skin Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit HORSHAM, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The conference is being held virtually on October 15 – 17, 2024. globenewswire.com - 6 months ago
8. Profile Summary

STRATA Skin Sciences, Inc. SSKN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 11.2 M
Dividend Yield 0.00%
Description STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Contact 5 Walnut Grove Drive, Horsham, PA, 19044 https://www.strataskinsciences.com
IPO Date Nov. 3, 2005
Employees 106
Officers Mr. Shmuel Gov Chief Operating Officer Dr. Dolev Rafaeli Ph.D. President, Chief Executive Officer & Vice-Chairman Mr. John Gillings Principal Financial Officer & Principal Accounting Officer Mr. Jay Sturm General Counsel & Corporate Secretary Mr. Michael R. Stewart Independent Consultant